Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease.

Mirikizumab-treated patients achieved statistically significant clinical remission and endoscopic response compared with placebo at week 52. The Food and Drug Administration (FDA) has approved ...

If you continue to have this issue please contact [email protected]. More than 80% of Omvoh responders from the VIVID-1 study maintained endoscopic response at week 104 in VIVID-2.

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. 2,3 "Many ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of ...

Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the ...